Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2010 - 2026)

Neurocrine Biosciences has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 9.09% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $26.6 million (up 7.26% YoY), and the FY2025 full-year result was $26.0 million, up 10.64% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $7.2 million, up from $6.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $7.2 million in Q1 2026, with the low at $3.3 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $5.3 million across 5 years, with a median of $5.3 million in 2024.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 52.38% — and 2025, when it dropped 1.56%.
• Neurocrine Biosciences' Depreciation & Amortization (CF) stood at $3.9 million in 2022, then increased by 25.64% to $4.9 million in 2023, then increased by 26.53% to $6.2 million in 2024, then advanced by 3.23% to $6.4 million in 2025, then increased by 12.5% to $7.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $7.2 million (Q1 2026), $6.4 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.